Current status and perspectives of immunomodulators of microbial origin.
The chemical structure and characteristics, the antitumour activity, the antibacterial, antiviral, antifungal, antiparasitic activities, immunological properties and mode of action of immunomodulators of microbial origin, especially antitumour polysaccharide lentinan, have been discussed immunopharmacologically in comparison with pachymaran, schizophyllan, DiLuzio's yeast glucan, Coriolus preparation PS-K, Streptococcal preparation OK-432, Nocardia rubra cell wall skeleton N-CWS together with BCG and Corynebacterium parvum. Lentinan exerts its inhibitory action not only on allogeneic tumours but also on syngeneic and autologous tumours, and prevents chemical and viral carcinogenesis. The phase III randomized control study of lentinan in cancer patients with gastric and colo-rectal cancer showed the clinical efficacy of lentinan in prolonging the life span and improving host immune responses. Experimental and clinical application demonstrated the advantage of N-CWS over BCG-CWS, and a recent study on OK-432 showed similar results to those obtained with C. parvum. In future work on microbial immunomodulators, it will be essential to find a parameter of the host-tumour relationship which will indicate the protocol for application of immunomodulators, and to find a new-type of selective immunostimulant. For this purpose, exhaustive studies on lymphokines, monokines and lymphocyte tropic hormones are indispensable.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use; D001419:Bacteria / Q000276:immunology*; D001798:Blood Proteins / Q000276:immunology; D002236:Carbohydrate Conformation; D055598:Chemical Phenomena; D002621:Chemistry; D003110:Colonic Neoplasms / Q000628:therapy; D005658:Fungi / Q000276:immunology*; D005936:Glucans / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007239:Infections / Q000628:therapy; D007912:Lentinan / Q000627:therapeutic use; D008214:Lymphocytes / Q000276:immunology; D008262:Macrophage Activation; D009374:Neoplasms, Experimental / Q000628:therapy; D010844:Picibanil / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011509:Proteoglycans / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000628:therapy; D012566:Sizofiran / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000628:therapy; D013329:Structure-Activity Relationship
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D001798:Blood Proteins; D005936:Glucans; D011134:Polysaccharides; D011509:Proteoglycans; D007912:Lentinan; D010844:Picibanil; C010770:polysaccharide-K; D012566:Sizofiran